DEAN Y. LI, MD
Osteopathic Medicine at Medical Dr, Salt Lake City, UT
License number
Utah 357340-1205
Category
Osteopathic Medicine
Type
Cardiovascular Disease
Address
Address
50 N Medical Dr, Salt Lake City, UT 84132
Phone
(801) 581-7715
(801) 213-3800
(801) 213-3800
Personal information
See more information about DEAN Y. LI at radaris.comName
Address
Phone
1416 S Wasatch Dr, Salt Lake City, UT 84108
1416 Wasatch St, Salt Lake Cty, UT 84108
Professional information
Dean Y Li, Salt Lake City UT
Specialties:
Cardiologist
Address:
15 N 2030 E, Salt Lake City, UT 84112
50 N Medical Dr, Salt Lake City, UT 84132
50 N Medical Dr, Salt Lake City, UT 84132
Education:
Doctor of Medicine
Board certifications:
American Board of Internal Medicine Sub-certificate in Cardiovascular Disease (Internal Medicine)
Dean Y Li, Salt Lake City UT
Specialties:
Cardiovascular Disease, Cardiology
Work:
Uumc Cardiology
50 N Medical Dr, Salt Lake City, UT 84132 Va Salt Lake City Health Care System
500 Foothill Dr, Salt Lake City, UT 84148 U Of Utah Cardiology Division
30 N 1900 E, Salt Lake City, UT 84132
50 N Medical Dr, Salt Lake City, UT 84132 Va Salt Lake City Health Care System
500 Foothill Dr, Salt Lake City, UT 84148 U Of Utah Cardiology Division
30 N 1900 E, Salt Lake City, UT 84132
Education:
Washington University at St. Louis (1990)
Transgenic Mouse With Endogenous Endoglin Gene Disruption
US Patent:
6372958, Apr 16, 2002
Filed:
May 25, 2000
Appl. No.:
09/578553
Inventors:
Dean Y. Li - Salt Lake City UT
Mark T. Keating - Salt Lake City UT
Mark T. Keating - Salt Lake City UT
Assignee:
The University of Utah Research Foundation - Salt Lake City UT
International Classification:
A01K 67027
US Classification:
800 18, 800 3, 800 22, 800 8, 800 9, 800 21
Abstract:
Transgenic mice are genetically engineered for a deficiency in endoglin production. These mice may have a homozygous or hemizygous disruption of the endogenous endoglin gene. Homozygous mice exhibit a lack of endoglin production. The failure to produce endoglin results in arrested development of the vascular system of the mouse and no survival beyond E11. 5. These mice and cells derived therefrom provide useful reagents for understanding the development and pathology of the mammalian vascular system.
Method Of Detecting Ocular Diseases And Pathologic Conditions And Treatment Of Same
US Patent:
2010012, May 27, 2010
Filed:
Dec 21, 2007
Appl. No.:
12/520055
Inventors:
Kang Zhang - San Diego CA, US
Zenglin Yang - Salt Lake City UT, US
Haoyu Chen - Salt Lake City UT, US
Dean Li - Salt Lake City UT, US
Zenglin Yang - Salt Lake City UT, US
Haoyu Chen - Salt Lake City UT, US
Dean Li - Salt Lake City UT, US
Assignee:
UNIVERSITY OF UTAH RESEARCH FOUNDATION - Salt Lake City UT
International Classification:
A61K 39/395
US Classification:
4241331, 4241301, 4241411
Abstract:
Ocular diseases affecting the macula or the vasculature of the eye affect a wide variety of individuals. In particular, Age-related macular degeneration (AMD) is the most common cause of irreversible vision loss in the developed world and has a significant genetic predisposition. Methods of analyzing one or more mutations in the HtrA1 gene in order to identify individuals with a presusceptability to development of an ocular disease and a pathologic condition of the eye and diagnose those currently suffering from an ocular disease or a pathologic condition of the eye are provided. The methods of the present invention may further include analysis of the CFH gene in order to identify individuals with a presusceptability to development of an ocular disease and a pathologic condition of the eye and diagnose those currently suffering from an ocular disease or a pathologic condition of the eye. Compositions and methods for treating ocular disease and pathologic conditions of the eye are also provided.
Compositions And Methods For Treating Ocular Pathologic Angiogenesis And Vascular Permeability
US Patent:
7994130, Aug 9, 2011
Filed:
Dec 11, 2007
Appl. No.:
12/518730
Inventors:
Dean Li - Salt Lake City UT, US
Christopher Jones - Salt Lake City UT, US
Nyall London - Bountiful UT, US
Christopher Jones - Salt Lake City UT, US
Nyall London - Bountiful UT, US
Assignee:
University of Utah Research Foundation - Salt Lake City UT
International Classification:
A61K 38/16, A61K 38/17, C07K 14/435
US Classification:
514 133, 514 212, 514 11, 530350
Abstract:
Compounds, compositions and methods for inhibiting vascular permeability and pathologic angiogenesis are described herein. Methods for producing and screening compounds and compositions capable of inhibiting vascular permeability and pathologic angiogenesis are also described herein. Pharmaceutical compositions are included in the compositions described herein. The compositions described herein are useful in, for example, methods of inhibiting vascular permeability and pathologic angiogenesis, including methods of inhibiting vascular permeability and pathologic angiogenesis induced by specific angiogenic, permeability and inflammatory factors, such as, for example VEGF, bFGF and thrombin. Methods for treating specific diseases and conditions are also provided herein.
Methods And Compositions For Manipulating The Guided Navigation Of Endothelial Tubes During Angiogenesis
US Patent:
2013014, Jun 6, 2013
Filed:
Oct 23, 2012
Appl. No.:
13/658526
Inventors:
Dean Y. Li - Salt Lake City UT, US
Kye Won Park - Salt Lake City UT, US
Kye Won Park - Salt Lake City UT, US
Assignee:
University of Utah Research Foundation - Salt Lake City UT
International Classification:
C12N 5/071, C07K 14/705
US Classification:
435375, 536 235, 530350
Abstract:
Methods and compositions for manipulating the directed navigation of physiological tracking tubular structures are provided. A novel cell-bound receptor, roundabout-4 (Robo-4), is described. The Robo-4 receptor shows sequence and structural similarity to members of the roundabout family of receptors. Also, the Robo-4 receptor binds Slit ligand, a known receptor of the roundabout receptors. Polynucleotides and polypeptides of the Robo-4 receptor are described.
Compositions And Methods For Inhibiting Vascular Permeability
US Patent:
8309519, Nov 13, 2012
Filed:
May 19, 2011
Appl. No.:
13/111776
Inventors:
Dean Li - Salt Lake City UT, US
Christopher Jones - Salt Lake City UT, US
Nyall London - Bountiful UT, US
Christopher Jones - Salt Lake City UT, US
Nyall London - Bountiful UT, US
Assignee:
University of Utah Research Foundation - Salt Lake City UT
International Classification:
A61K 38/16, A61K 38/17, C07K 14/435
US Classification:
514 133, 514 212, 514 11, 530350
Abstract:
Compounds, compositions and methods for inhibiting vascular permeability and pathologic angiogenesis are described herein. Methods for producing and screening compounds and compositions capable of inhibiting vascular permeability and pathologic angiogenesis are also described herein. Pharmaceutical compositions are included in the compositions described herein. The compositions described herein are useful in, for example, methods of inhibiting vascular permeability and pathologic angiogenesis, including methods of inhibiting vascular permeability and pathologic angiogenesis induced by specific angiogenic, permeability and inflammatory factors, such as, for example VEGF, bFGF and thrombin. Methods for treating specific diseases and conditions are also provided herein.
Method Of Detecting Ocular Diseases And Pathologic Conditions And Treatment Of Same
US Patent:
2010016, Jul 1, 2010
Filed:
Oct 8, 2007
Appl. No.:
12/444558
Inventors:
Kang Zhang - San Diego CA, US
Zenglin Yeng - Salt Lake City UT, US
Haoyu Chen - Salt Lake City UT, US
Dean Li - Salt Lake City UT, US
Zenglin Yeng - Salt Lake City UT, US
Haoyu Chen - Salt Lake City UT, US
Dean Li - Salt Lake City UT, US
Assignee:
UNIVERSITY OF UTAH RESEARCH FOUNDATION - Salt Lake City UT
International Classification:
A61K 39/395, C07K 16/18, A61P 27/02
US Classification:
4241331, 4241301, 4241411, 5303871
Abstract:
Methods of detecting and treating diseases and pathological conditions of the eye are disclosed. In particular a genetic variant of the HtrA1 gene is correlated to age related macular degeneration (AMD). In addition, biologically active agents capable of inhibiting HtrA1 activity are provided, and methods of treating diseases and pathological conditions of the eye are additionally disclosed.
Manipulation Of Arterial-Venous Identity
US Patent:
2002008, Jun 27, 2002
Filed:
Aug 3, 2001
Appl. No.:
09/921771
Inventors:
Dean Li - Salt Lake City UT, US
International Classification:
A61K048/00, C12N015/86
US Classification:
424/093210, 435/456000, 514/044000
Abstract:
Methods and compositions for manipulating the arterial-venous identity of endothelial cells are provided. The methods comprise introducing an arterial molecular program into endothelial cells of a vein section such that the endothelial cells can remodel to form arterial endothelial cells. The arterial molecular program can comprise one or more polynucleotides encoding various genes that are associated with arterial development and/or differentiation from veins. Expression vectors comprising the genes can be used to introduce the molecular program into the cells. A method of treating a patient having an obstructed blood vessel is also provided.
Tropoelastin For Promoting Endothelial Cell Adhesion Or Migration
US Patent:
2009028, Nov 12, 2009
Filed:
Feb 24, 2006
Appl. No.:
11/885105
Inventors:
Dean Y. Li - Salt Lake City UT, US
Brent D. Wilson - Salt Lake City UT, US
Lise Sorensen Brunhart - Salt Lake City UT, US
Brent D. Wilson - Salt Lake City UT, US
Lise Sorensen Brunhart - Salt Lake City UT, US
International Classification:
A61F 2/00, C12N 5/02, C12N 11/02, A61K 38/00
US Classification:
424423, 435375, 435177, 514 2
Abstract:
The invention provides methods, compositions, and devices for promoting adhesion or migration of endothelial cells.